ESR1 and breast carcinoma: Triple‐negative breast cancer (TNBC), accounting for 15%–20% of breast cancer (BC) population, lacks hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) expression and Her2 amplification/overexpression.1